CYB003 also demonstrated an excellent safety profile, with no new adverse events reported in the 12- month follow-up, including no reports of suicidality.
What is covered in the Full Insight:
Introduction to CYB003 Data
Phase 2 Efficacy Results
Phase 3 Program Details
Upcoming Catalysts
Market and Valuation
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.